Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Esophageal Cancer.

CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Adenocarcinoma.

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

FGFR1-targeting Pemazyre was approved by the ... At the moment, FGFR2 and FGFR3 inhibitor Balversa is only FDA-approved for bladder cancer. Around 25,000 people in Japan are diagnosed with biliary ...